John Öhd, Modus Therapeutics' CEO, commented:” Modus has strategically partnered with Latis for our upcoming study in Italy, recognizing the importance of aligning with a CRO that understands both the scientific landscape and the specific needs of our company. Our longstanding collaboration with prominent preclinical and clinical experts in the field from the University of Brescia and the University Hospital in Verona, highlights the value of operating within this robust scientific ecosystem, where Latis’s local expertise will be instrumental in driving our groundbreaking research forward.”

The second quarter in figures

• The loss after tax amounted to TSEK 4 738 (4 695).
• The loss per share amounted to SEK 0,13 (0,29).
• The cash flow from current operations was negative in the amount of TSEK 3 424 (4 267).

The first half-year in figures

• The loss after tax amounted to TSEK 7 843 (10 735).
• The loss per share amounted to SEK 0,22 (0,67).
• The cash flow from current operations was negative in the amount of TSEK 7 089 (10 602).

Important events during the second quarter

• The annual general meeting was held on May 17.
• Modus Therapeutics participated in Pharma partnering summit, Basel.

Important events after the end of the period
No event to report.

CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on August 23 at 14:00 Link to Interview: https://www.youtube.com/watch?v=3CH3AHoOTdc